Advancements in the treatment for diabetes and cardiovascular complications in the last decade completely changed the landscape of these diseases. Newly developed medications significantly reduce the risk of cardiovascular complications and slow down the progression of diabetes, while innovative surgical technologies substantially improve the survival rates from the lethal complications. However, the emergence of advanced techniques comes with high expenses, which create huge barriers for access and worsens the disparity in health outcomes. Meanwhile, the use of these technologies calls for post-marketing surveillance in real world. How did new technologies adapt in the developed/developing countries? What is the cost for these treatments? Did these new treatments lead to improved healthcare quality? Many issues are unknown and thus we invite further investigation.
This Research Topic seeks to draw a comprehensive picture of the current epidemiology and treatment of diabetes and cardiovascular diseases across the globe. We hope to publish high-quality articles that describe the epidemiology, economic, treatment, and disparity of diabetes and cardiovascular disease in the context of the new treatment era. Findings published in this Research Topic will enlighten an interesting discussion on how technological advancements shaped the landscape of diabetes and cardiovascular disease. It will also help identify gaps to be resolved in countries with different economic and social backgrounds across the globe.
We welcome contributions of a range of topics including, but not limited to:
• Contemporary epidemiology study focusing on the disease burden of diabetes and cardiovascular disease;
• Economic burden of diabetes and cardiovascular disease;
• Drug, new technology and service utilization for managing diabetes and cardiovascular disease;
• Effectiveness and safety of treatment for diabetes and cardiovascular disease;
• Policy studies involving the use of new treatments and technologies in patients with diabetes and cardiovascular disease;
Topic editor, Hui Shao, receives research funding from Sanofi and AstraZeneca. All other Topic Editors declare no competing interests with regard to the Research Topic subject.
Advancements in the treatment for diabetes and cardiovascular complications in the last decade completely changed the landscape of these diseases. Newly developed medications significantly reduce the risk of cardiovascular complications and slow down the progression of diabetes, while innovative surgical technologies substantially improve the survival rates from the lethal complications. However, the emergence of advanced techniques comes with high expenses, which create huge barriers for access and worsens the disparity in health outcomes. Meanwhile, the use of these technologies calls for post-marketing surveillance in real world. How did new technologies adapt in the developed/developing countries? What is the cost for these treatments? Did these new treatments lead to improved healthcare quality? Many issues are unknown and thus we invite further investigation.
This Research Topic seeks to draw a comprehensive picture of the current epidemiology and treatment of diabetes and cardiovascular diseases across the globe. We hope to publish high-quality articles that describe the epidemiology, economic, treatment, and disparity of diabetes and cardiovascular disease in the context of the new treatment era. Findings published in this Research Topic will enlighten an interesting discussion on how technological advancements shaped the landscape of diabetes and cardiovascular disease. It will also help identify gaps to be resolved in countries with different economic and social backgrounds across the globe.
We welcome contributions of a range of topics including, but not limited to:
• Contemporary epidemiology study focusing on the disease burden of diabetes and cardiovascular disease;
• Economic burden of diabetes and cardiovascular disease;
• Drug, new technology and service utilization for managing diabetes and cardiovascular disease;
• Effectiveness and safety of treatment for diabetes and cardiovascular disease;
• Policy studies involving the use of new treatments and technologies in patients with diabetes and cardiovascular disease;
Topic editor, Hui Shao, receives research funding from Sanofi and AstraZeneca. All other Topic Editors declare no competing interests with regard to the Research Topic subject.
